Related Experiment Video
Updated: Aug 10, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis
Liyun Zou1, Yuzhang Wu, Li Pei
1Institute of Immunology of PLA, Third Military Medical University, Chongqing 400038, PR China.
Insights
Researchers identified novel leukemia-associated antigens (LAAs) in chronic myeloid leukemia (CML) using serology and proteomics. These LAAs could be valuable for CML screening, diagnosis, and developing new immunotherapies.
Area of Science:
- Immunology
- Oncology
- Proteomics
Background:
- The immune system is crucial for treating chronic myeloid leukemia (CML).
- Identifying leukemia-associated antigens (LAAs) is essential for developing specific immunotherapies for CML.
Purpose of the Study:
- To discover novel LAAs in CML patients.
- To explore the potential of these LAAs in CML diagnosis and immunotherapy.
Main Methods:
- Employed a novel approach combining serology and proteomics.
- Utilized two-dimensional gel electrophoresis (2-DE) to resolve proteins.
- Compared protein reactivity with sera from CML patients and healthy donors.
Main Results:
- Identified several new LAAs, including alpha enolase, aldolase A, HSP70 protein8, beta-tubulin, and tropomyosin isoforms.
- Detected autoantibodies against these identified proteins in CML patients.
Conclusions:
- The identified LAAs and associated autoantibodies may aid in CML screening, diagnosis, and patient follow-up.
- These novel LAAs hold significant potential for advancing antigen-based immunotherapy in CML.
Abstract:
The immune system plays an important role in the treatment of chronic myeloid leukemia (CML). Identification of leukemia-associated antigens (LAAs) eliciting an immune response in patients is a prerequisite for specific immunotherapy of CML. To identify new LAAs in CML, We utilized a novel approach based serology and proteomics technologies. LAAs were identified by comparing the reactivity of proteins resolved by 2-DE with sera from CML patients and healthy donors. Several new LAAs were identified including alpha enolase, aldolase A, HSP70 protein8, beta-tubulin and tropomyosin isoforms. Although, the functions of these identified proteins in CML need further investigation, the detection of autoantibodies in CML may have value on CML screening, diagnosis, or follow-up. Additionally, identification of LAAs in CML may also be of vital importance in antigen-based immunotherapy.
